Amniotic membrane allografts: development and clinical utility in ophthalmology

Allison Rizzuti1,2
Adam Goldenberg1
Douglas R Lazzaro1,2
1SUNY Downstate Medical Center, 2Kings County Hospital Center, Brooklyn, NY, USA

Abstract: Amniotic membrane, the innermost layer of the placenta, is a tissue that promotes epithelialization, while decreasing inflammation, neovascularization, and scarring. It is used in the surgical management of a wide variety of ophthalmic conditions where it functions as a graft or patch in ocular surface reconstruction. The development of new preservation techniques, as well as a sutureless amniotic membrane, has allowed for easier, in-office placement, without the disadvantages of an operating room procedure. The purpose of this review is to describe the historical development of amniotic membrane in ophthalmology and to describe its current clinical applications, particularly focusing on recent advances.

Keywords: ocular surface, cornea, stem cells, prokera, allograft, patch, transplantation

Introduction
Amniotic membrane is the innermost layer of the placenta, which after proper cryopreservation techniques, is used to treat a wide variety of ophthalmic conditions. By serving as a basement membrane, amniotic membrane promotes epithelialization at the site of a tissue defect in order to effectively reconstruct the ocular surface. It has also been shown to decrease inflammation, neovascularization, and scarring, as well as to possess antimicrobial and analgesic effects. Its unique properties make the amniotic membrane a suitable substrate for the ex vivo growth of stem cells, and it is currently being used to facilitate stem cell transplants for patients with limbal stem cell deficiency. The development of the sutureless Prokera® (Bio-Tissue, Inc., Doral, FL, USA) and AmbioDisk™ (Katena/IOP, Costa Mesa, CA, USA) have allowed for an easier in-office application, eliminating the need for an operating room procedure. Herein, we review the development of the amniotic membrane and its clinical applications in ophthalmology, particularly focusing on recent advances.

Historical perspective
The use of amniotic membrane as a skin graft was first reported in 1910 by Dr JW Davis at the suggestion of WL Thorton, a third-year medical student at Johns Hopkins.1 While this initial trial was unsuccessful, Sabella2 and Stern3 independently and successfully utilized amniotic membrane grafts as a treatment for burn patients. Preservation processes developed in the 1940s demonstrated that amniotic tissue could be processed and stored, thereby increasing its utility. Through time and experimentation, amniotic membrane grafts were found to be highly versatile, leading to their usage in a variety of fields including oral wound healing,4 otolaryngology,5 repair...
of myelomeningoceles, vaginal reconstructive surgery, neural repair in animal models, the prevention of surgical adhesions, closure of pericardium, and for ocular surface reconstruction.

The first report of amniotic membrane as a corneal graft was by De Röth in 1940 as an attempt to find a tissue, which was similar to and more readily available than a corneal allograft. While this initial attempt was largely unsuccessful, British ophthalmologists Sorsby et al were successful in implementing amniotic membranes as corneal grafts resulting in the treatment of a total of 58 patients with caustic burns of the eye. Although the success of Sorsby et al with corneal amniotic membrane grafting was later replicated, the use of amniotic membranes as a corneal graft went relatively unreported for the next 30 years for no apparent reason, other than Collin’s mention that “working with fetal membranes, however, is extremely difficult”.

Although unreported, preserved amniotic membrane was secretly and successfully used as a treatment for corneal damage in Soviet Russia. The analysis and subsequent discovery of the identity of this tissue as amniotic membrane by Batlle and Perdomo sparked Schaffer Tseng et al to reintroduce and expand this tissue’s role in ocular reconstruction through the development of new methods of preservation, and to develop new surgical techniques.

**Mechanism of action and procurement**

The exact mechanism by which amniotic membrane serves to reconstruct a damaged ocular surface remains unclear, but it is thought that its high concentrations of cytokines and growth factors act to promote epithelial growth, while suppressing inflammation and scarring. Amniotic membrane acts as a basement membrane, which facilitates the migration of epithelial cells, reinforces adhesion, promotes differentiation, and prevents cellular apoptosis. The properties of amniotic membrane and the associated factors are extensive and beyond the scope of this review, but are briefly outlined in Table 1.

Amniotic membrane is obtained from consenting donors who are screened in the prenatal unit, excluding mothers with a drug or alcohol history and those with communicable diseases such as human immunodeficiency virus and hepatitis. The placenta is collected after elective cesarian section delivery and the amnion is isolated under sterile conditions, as described by Lee and Tseng. Although it has been suggested that fresh amniotic membrane is superior in terms of its anti-inflammatory properties, the membrane is cryopreserved in order to prevent the transmission of blood-borne illnesses. It is stored in 50% glycerol and spread epithelial side up on nitrocellulose paper. The tissue is then frozen to –80°C and may be stored for 2 years’ post-delivery.

**Clinical uses in ophthalmology**

Amniotic membrane transplantation (AMT) is used in various ways to treat a wide variety of ophthalmic conditions. It is composed of a single epithelium layer, a thick basement membrane, and an avascular stroma. Depending on its placement and orientation, the membrane may serve as a permanent graft, a temporary patch, or may be used as a combination of both. As a graft, the amniotic membrane is placed at the site of a corneal or conjunctival tissue defect caused by a disease process or created by previous surgery.

**Table 1 Properties and factors of amniotic membrane**

<table>
<thead>
<tr>
<th>Amniotic membrane function</th>
<th>Factors present in amniotic membrane</th>
<th>Down-regulated factors</th>
</tr>
</thead>
<tbody>
<tr>
<td>Promoter of epithelialization</td>
<td>Epidermal growth factor (EGF), keratinocyte growth factor (KGF), transforming growth factor-α (TGF-α), basic fibroblast growth factor (bFGF), transforming growth factor-β (TGF-β) 1,2,3, keratinocyte growth factor receptor (KGRFR), hepatocyte growth factor receptor (HGF), trefoil factor family 3 peptide (TFF-3)</td>
<td>Matrix metalloproteinase 2 (MMP-2), MMP-9</td>
</tr>
<tr>
<td>Suppresses angiogenesis</td>
<td>Collagen α1 XVIII (Col α1 XVIII), thrombospondin 1 (TSP-1), tissue inhibitor of metalloprotease (TIMP)-1, TIMP-2, TIMP-3, TIMP-4, interleukin-10 (IL-10), IL-1RA, pigment epithelium derived factor (PEDF), heavy chain-hyaluronic acid (HC-HA)</td>
<td></td>
</tr>
<tr>
<td>Suppression of inflammation</td>
<td>IL-10, IL-1RA, HC-HA</td>
<td>TGF-β1, TGF-β2, TGF-β3, IL-6, TNF-α, IL-1α, IL-1β, IL-8</td>
</tr>
<tr>
<td>Suppression of scarring</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Antimicrobial</td>
<td>Human β-defensins 1–4, elafin, secretory leukocyte proteinase inhibitor (SLPI), cystatin E</td>
<td></td>
</tr>
</tbody>
</table>
The graft is placed epithelial side up and provides a base-
ment membrane and stroma onto which normal epithelium
can grow. It helps to reduce inflammation and scarring and
will ultimately become integrated into the host tissue. As a
patch, the amniotic membrane is placed with the epithelial
side facing down. The patch covers an epithelial defect and
suppresses acute inflammation in order to promote healing
of the tissue underneath. The membrane is then removed,
resorbed, or falls off. Occasionally, the methods are com-
bined, and a patch is placed in order to cover and protect an
underlying graft. The amniotic membrane integrates itself
into the host cornea in different patterns depending on the
particular ocular surface disorder or surgical technique used,
as described by Resch et al.18

Amniotic membrane may be secured to the cornea or
conjunctiva with sutures or with tissue adhesive such as
fibrin glue. Prokera is a cryopreserved amniotic membrane
that is secured to a dual polycarbonate ring and is placed in
the eye similar to a contact lens, eliminating the need for
sutures or glue. A recent study evaluating the indications and
outcomes of Prokera in the management of ocular surface
disorders concluded that it is easy to use and well tolerated,
with moderate success in corneal ulcers and encouraging
results in acute moderate chemical injury. The authors found
recurrences of the primary condition in cases where it was
used in dry eye and neurotrophic keratitis.19

In recent years, freeze-dried amniotic membrane has
become an alternative to cryopreserved amniotic membrane,
offering the advantage of easier surgical handling and elimi-
nating the need for temperature-controlled transportation.
Ambio2™ (IOP Ophthalmics), Ambio5® (IOP Ophthalmics),
and AmbioDisk are available in different sizes, are placed on
the surgical site while dry, and are activated with sterile saline.
Long-term storage of the cryopreserved amniotic membrane
in the cell culture media with 50% glycerol was found to
have no significant effect on sterility, histology, or biological
properties of the membrane.20 Additionally, a recent study on
augmented dried versus cryopreserved amniotic membrane
found that freeze-dried amniotic membrane pretreated with
lyoprotectants is more effective than conventional intact
cryopreserved amniotic membrane.21

**Limbal stem cell deficiency (LSCD)**

Amniotic membrane is frequently used to treat conditions of
partial or total LSCD.22 LSCD may be congenitally acquired
but is more commonly seen after chemical and thermal
burns, as well as inflammatory conditions such as Stevens
Johnson syndrome (SJS), and ocular cicatricial pemphigoid.
The limbal stem cells reside at the corneoscleral limbus, and
their disruption leads to visual impairment by conjunctival-
ization and vascularization with subsequent loss of corneal
transparency. Patients with LSCD may complain of loss of
vision, tearing, photophobia, and recurring episodes of pain.
The treatment of LSCD depends on whether the condition
is partial, total, unilateral, or bilateral. Corneal transplants
often fail, and the condition is most often managed with
ocular surface reconstruction with or without limbal stem
cell transplantation.

Partial LSCD may not require a stem cell transplant, and
has been treated successfully by simple debridement with or
without AMT. Tseng et al22 used AMT to treat 42 patients
with partial and total LSCD and concluded that patients with
partial LSCD could be treated with AMT alone, but those
with total LSCD needed AMT in combination with limbal
stem cell transplantation. Konomi et al23 recently reported on
amniotic membrane patch or amniotic membrane graft with
patch, placed after excising abnormal conjunctival tissue for
LSCD and concluded that while this method may provide
temporary improvement, it does not maintain long-term
stability of the ocular surface.23

Ocular surface reconstruction in combination with stem
cell transplantation is required to successfully treat total
stem cell deficiency. If the damage is unilateral, donor stem
cells may be obtained from the unaffected eye (conjunctival
limbal autograft). In this case, there is no need for systemic
immunosuppression, as there is no risk of graft rejection.
A study has shown successful outcomes in greater than
80% of these cases, with regression of vascularization and
restoration of corneal clarity.24 Sangwan et al25 introduced a
simple technique for the treatment of LSCD, in which a
donor limbal graft from the unaffected eye is cut into small
pieces and then expanded in the recipient eye with the help
of amniotic membrane and fibrin glue. Amescua et al26 modi-
fied this technique by using a double amniotic membrane
graft to protect the stem cell graft. Both techniques report a
100% graft success rate, restoration of corneal epithelium,
and an improvement in visual acuity.25,26 The use of amniotic
membrane to aid in vivo expansion requires a small tissue
size and avoids the need for systemic immunosuppression,
as required in keratolimbal allografts, with success rates
comparable to conventional techniques.

If the total stem cell deficiency is bilateral, donor stem cells
may be obtained from a living relative (conjunctival allograft)
or cadaver (keratolimbal allograft). These techniques carry the
risk of graft rejection, and patients need to be placed on
systemic immunosuppression. Amniotic membrane is used to
facilitate the growth of the limbal stem cells in vivo as well as to expand limbal stem cells ex vivo, before being transferred to the recipient eye. While the success rates of autografts are similar to that of conjunctival autografts in the first 1–2 years, the success rate drops due to graft failure at 5 years.

AMT has also recently shown promising results in the treatment of SJS or toxic epidermal necrolysis during the acute phase in order to prevent the cicatricial changes associated with chronic disease. The amniotic membrane is bolstered to the eyelids, as it must cover the entire ocular surface. The authors concluded that early AMT prevents severe vision loss in SJS/toxic epidermal necrolysis patients with initial moderate-to-severe ocular surface inflammation.

Corneal epithelial defects and ulcers
Persistent epithelial defects (PEDs) are corneal wounds in which the corneal epithelium fails to regenerate in a normal time period. They may occur in situations of poor wound healing from neurotrophic or exposure keratopathy, dry eye, or inflammation. PEDs are conventionally treated with punctual occlusion and frequent lubrication with artificial or autologous tears (serum spun down from patient with a corneal defect). The use of amniotic membrane for PEDs was first reported by Lee et al in 1997. After epithelial debridement, an amniotic membrane patch may be sutured or glued, or a sutureless graft may be placed. If the defect involves several layers of the stroma, the membrane may be placed as a graft. Healing can be further promoted by placing a temporary tarsorrhaphy. AMT has shown an average success rate of 79% (range, 67%–91%), with rapid and complete healing of the PED within 1–4 weeks. Hick et al reported on their experience using AMT in 33 eyes of 32 patients with non-healing ulcers from a variety of causes including neurotrophic, autoimmune, and infectious etiologies. Fourteen of the ulcers were perforated, and these were managed by applying fibrin glue to the perforation site followed by AMT. Thirty of 33 eyes (90%) epithelialized within 3.6±1.6 weeks and had a stable corneal surface at least for 2 months after the surgery.

AMT in combination with debridement has also been shown to be an effective surgical modality for severe shield ulcers associated with vernal keratoconjunctivitis. A recent study evaluating the clinical outcomes and complications of shield ulcers by various treatment methods concluded that Grade 1 shield ulcers responded well to medical therapy alone, Grade 2 ulcers occasionally required additional debridement or AMT, while Grade 3 ulcers required debridement and AMT for rapid re-epithelialization.

Amniotic membrane for the treatment of Mooren’s ulcer has shown conflicting results, likely due to varying ulcer severity. A retrospective study of 18 eyes reported a stabilization of the visual acuity and rapid healing of the epithelial defect after single AMT in most cases. A recent study of eleven eyes found that AMT was not effective in curing severe forms of Mooren’s ulcer.

Bullous keratopathy
While corneal transplantation is the first line treatment for pseudophakic bullous keratopathy (PBK) in patients with good visual potential, AMT is a less invasive option to relieve pain in those patients whose visual prognosis remains poor. Piris et al first described the technique in which bullous epithelium was debrided and an amniotic membrane was sutured to the stroma and covered by a bandage contact lens. Ninety percent of the 50 patients who had intolerable pain preoperatively were pain-free 33.8 weeks after the AMT. AMT has been shown to be comparable in efficacy to both anterior stromal micropuncture and phototherapeutic keratectomy for the management of symptomatic PBK, and the authors suggest that combining AMT with either anterior stromal micropuncture or phototherapeutic keratectomy may improve efficacy.

Pterygium and conjunctival reconstruction
Pterygium is a common benign growth of the conjunctiva that is thought to be the result of ultraviolet light exposure. While initially asymptomatic, the growths can be associated with dry-eye symptoms, as they cause irregular wetting of the ocular surface. Further growths can cause an unpleasing cosmetic appearance, as well as visual changes due to induced astigmatism or their approach onto the visual axis. There are several surgical techniques used in the treatment of pterygia, with the overall goal to remove and prevent recurrence. Pterygium excision with conjunctival autograft is associated with recurrence rates as low as 2%, but it is more challenging, time consuming, and may also pose a problem for those patients needing future glaucoma surgery. Amniotic membrane is often used as an alternative to prevent pterygium recurrence. After the pterygium is removed, the amniotic membrane graft is sutured or glued to the bare sclera. A recent study comparing the efficacy of conjunctival autograft to AMT for the treatment of pterygium found that 7.4% of the conjunctival autograft group versus 19.2% of the amniotic membrane group...
recurred. Sekeroglu et al reported a technique combining AMT with a narrow strip conjunctival autograft for the treatment of pterygium where 93.3% of 30 eyes had no recurrence after 1 year of follow-up. We have attached a short video demonstrating this technique (Video S1).

Amniotic membrane has been used for various other conjunctival defects and abnormalities. Palamar et al recently reported on their experience using amniotic membrane for ocular surface reconstruction following the excision of ocular surface squamous neoplasia and found it to be effective for large conjunctival defects. Yang et al recently reported that patients with severe chronic atopic keratoconjunctivitis could benefit from surgical management using amniotic membrane. Amniotic membrane has also been used to prevent scarring in trabeculectomy. A recent study by Khairy et al found that AMT with trabeculectomy had an intraocular pressure-lowering effect comparable to that achieved with the use of mitomycin C, with a reduced rate of postoperative complications.

Conclusion
Amniotic membrane is being used extensively in ophthalmology, with a recent increase in its indications and techniques. It is used acutely for the management of ocular inflammatory conditions such as SJS, and it is also used to treat chronic changes of the eye such as in PBK. The ability of amniotic membrane to expand stem cells, both in vivo and ex vivo, has prompted major advancements in the treatment of LSCD. While it is most commonly used as a surgical modality for various conditions, the development of sutureless grafts has allowed for amniotic membrane placement in the office setting avoiding the time, expense, and complications that may be associated with a surgical procedure. New uses for amniotic membrane are on the horizon as its structure and mechanism of action become even better understood, and as new methods of preservation and delivery are introduced.

Acknowledgment
This study was supported in part from an RPB grant.

Disclosure
The authors report no conflicts of interest in this work.

References


